Edition:
United Kingdom

People: H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

408.70DKK
19 Oct 2018
Change (% chg)

kr.-6.60 (-1.59%)
Prev Close
kr.415.30
Open
kr.413.80
Day's High
kr.414.20
Day's Low
kr.408.10
Volume
170,955
Avg. Vol
320,182
52-wk High
kr.477.70
52-wk Low
kr.280.80

Anastasiou, Peter 

Mr. Peter E. Anastasiou has been appointed Executive Vice President, North America at H. LUNDBECK A/S, effective as of November 1, 2017. Peter Anastasiou serves as President of Lundbeck North America, overseeing the operations of both the U.S. and Canadian businesses. Peter Anastasiou has been with Lundbeck since 2009 and has since early 2016 served as President of Lundbeck U.S. where he oversees all aspects of the U.S. value chain, directing all Commercial, Drug Development and Corporate activities. Prior to that he served as U.S. Chief Commercial Officer, during which time he directed the Commercial operations of the company’s Psychiatry and Neurology franchises. Since mid-2016, Peter Anastasiou has had the responsibility for North America including Canada. Before joining Lundbeck, Peter Anastasiou held a series of leadership roles within neuroscience-focused pharmaceutical organizations. He served as Vice President of Marketing and Reimbursement at Neuronetics, Inc., and as Director of Abilify U.S. Marketing at Bristol-Meyers Squibb Company. He began his career at Eli Lilly and Company, where he held a variety of Marketing and Sales positions over the course of 11 years, including participation in the global launch of Cymbalta. He is Member of the Board of The Bear Necessities Pediatric Cancer Foundation and PhRMA (Pharmaceutical Research and Manufacturers of America).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --